Chronopin: upcoming release dates, events and other important dates

On 27 October 2026 Kalshi put an official Bloomberg IPO confirmation at 3.5% before Jan 1, 2027, rising to 50% before Jan 1, 2030. The largest step in the ladder runs from Jul 1, 2028 to Jan 1, 2029 (24% to 35%), so that window is the market's most likely stretch; it is a bet on timing, not a listing date.

AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Los Angeles hosts its third Games after 1932 and 1984, using almost entirely existing venues.

Los Angeles is preparing to host the 2028 Summer Olympics with zero new venues and a 'no-car' transit plan, a bold bet for a city not known for its public transport.

ERCOT identifies Amerada Storage as 26INR0084, Amerada Solar LLC, 150.78 MW in Freestone County, targeting July 21, 2028. Screening is complete and full study started without an IA; this is a development request.

Totality passes directly over central Sydney for nearly four minutes, the first there since 1857.

Roche's phase 3 trial of Enicepatide in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

The five-year UPS-Teamsters agreement covering some 340,000 workers expires on 31 July 2028, and the union's president has already said a strike is coming.

C24-005 is a 300 MW battery storage interconnection request in Bronx, NY. The grid operator lists its queue status as Active interconnection request. The requested in-service date is 2028-08-01; this is a planning date.

EIA August 2026 lists Cypress Creek’s Steel River Solar Phase 1, plant 70397, with 500 MW solar SRSP1 and separate 250 MW battery SRSB1, under construction at most 50% complete and planned for August 2028. Operator announced groundbreaking for the first two phases in July 2026.

AstraZeneca's phase 3 trial of AZD6234 in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity.

LA28’s first Paralympic Games open August 15, 2028 at SoFi Stadium in Inglewood and run through August 27. The Coliseum hosts the closing ceremony, so the opening pin is mapped to SoFi.

Boehringer Ingelheim's phase 3 trial of BI 690517 in kidney disease, chronic reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 11,000 participants. This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation.

A proposed redevelopment of the historic domiciliary campus with more than 220 mixed-income affordable homes and a full veterans preference. This is independent housing, distinct from the adjacent care facility. Property information reviewed October 10, 2026.

Estimated operation/completion target: August 2028. 754 MW generating capacity; About USD 1.2 billion published project cost. Under construction.

Separate construction cost, IT power, floor area and an opening date for this building or phase have not been verified. Published campus figures do not establish independent component figures.

MISO lists active J3723 as a 300 MW solar request in Wexford County, Michigan, at Keystone–Ludington 345 kV. The Phase 2 request has a September 1, 2028 in-service target; METC is transmission owner.